Lots of excitement about the role of PKM2 expression in cancer since the 2008 paper from the Cantley lab.  Now seems to be much more complex in vivo and may not be such a hot target for cancer therapy.   Will this dampen the general enthusiasm for cancer therapies targeting metabolism?

Comment